Researchers find new treatment for lethal resistant prostate cancers
In a study on mice, researchers found that the drugs, called Hsp90 inhibitors, were found to strip cancer cells of defences against hormone treatments. The research indicates that
Vertex has signed a definitive agreement to purchase Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired.
CTP-656 is a novel deuterium-modified version of ivacaftor. Ivacaftor is commercially available under the name Kalydeco®. The clinical trial results continue to support the development of CTP-656 as